NIHR CLAHRC West, University Hospitals Bristol NHS Foundation Trust, 9th Floor, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK.
Bristol Medical School, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK.
Support Care Cancer. 2018 May;26(5):1635-1644. doi: 10.1007/s00520-017-4002-3. Epub 2017 Dec 6.
We conducted a systematic review and individual patient data (IPD) meta-analysis to examine the utility of cystatin C for evaluation of glomerular function in children with cancer.
Eligible studies evaluated the accuracy of cystatin C for detecting poor renal function in children undergoing chemotherapy. Study quality was assessed using QUADAS-2. Authors of four studies shared IPD. We calculated the correlation between log cystatin C and GFR stratified by study and measure of cystatin C. We dichotomized the reference standard at GFR 80 ml/min/1.73m and stratified cystatin C at 1 mg/l, to calculate sensitivity and specificity in each study and according to age group (0-4, 5-12, and ≥ 13 years). In sensitivity analyses, we investigated different GFR and cystatin C cut points. We used logistic regression to estimate the association of impaired renal function with log cystatin C and quantified diagnostic accuracy using the area under the ROC curve (AUC).
Six studies, which used different test and reference standard thresholds, suggested that cystatin C has the potential to monitor renal function in children undergoing chemotherapy for malignancy. IPD data (504 samples, 209 children) showed that cystatin C has poor sensitivity (63%) and moderate specificity (89%), although use of a GFR cut point of < 60 ml/min/1.73m (data only available from two of the studies) estimated sensitivity to be 92% and specificity 81.3%. The AUC for the combined data set was 0.890 (95% CI 0.826, 0.951). Diagnostic accuracy appeared to decrease with age.
Cystatin C has better diagnostic accuracy than creatinine as a test for glomerular dysfunction in young people undergoing treatment for cancer. Diagnostic accuracy is not sufficient for it to replace current reference standards for predicting clinically relevant impairments that may alter dosing of important nephrotoxic agents.
我们进行了系统评价和个体患者数据(IPD)荟萃分析,以研究胱抑素 C 用于评估癌症患儿肾小球功能的效用。
合格的研究评估了胱抑素 C 在接受化疗的儿童中检测肾功能不全的准确性。使用 QUADAS-2 评估研究质量。四项研究的作者共享了 IPD。我们根据研究和胱抑素 C 测量方法对胱抑素 C 的对数和 GFR 进行分层,计算相关性。我们将参考标准分为 GFR 80 ml/min/1.73m,将胱抑素 C 分为 1 mg/L,以计算每项研究和根据年龄组(0-4 岁、5-12 岁和≥13 岁)的敏感性和特异性。在敏感性分析中,我们研究了不同的 GFR 和胱抑素 C 切点。我们使用逻辑回归估计肾功能不全与胱抑素 C 对数的关联,并使用 ROC 曲线下面积(AUC)量化诊断准确性。
六项研究使用不同的检测和参考标准阈值,表明胱抑素 C 有可能监测恶性肿瘤化疗儿童的肾功能。IPD 数据(504 个样本,209 名儿童)表明,胱抑素 C 的敏感性(63%)较低,特异性(89%)中等,尽管使用<60 ml/min/1.73m 的 GFR 切点(仅来自两项研究的数据)估计敏感性为 92%,特异性为 81.3%。综合数据集的 AUC 为 0.890(95%CI 0.826,0.951)。诊断准确性似乎随年龄而降低。
胱抑素 C 作为癌症治疗青少年肾小球功能障碍的检测方法,其诊断准确性优于肌酐。诊断准确性还不足以替代当前预测可能改变重要肾毒性药物剂量的临床相关损害的参考标准。